Navigation Links
GlaxoSmithKline Share Their Insight on Understanding DDI With a View to Better Prediction and Control
Date:6/28/2012

LONDON, June 28, 2012 /PRNewswire/ --

Pharma IQ has released a new interview with Dr. James Clarke, Senior Scientist, GlaxoSmithKline, on the biggest challenges for clinically relevant drug transporters that GSK faces.

In this exclusive podcast Dr. Clarke shares his knowledge on how drug transporters exert a vital influence on drug absorption, disposition, metabolism and elimination and why they are an essential part of predicting drug disposition. He provides ideas on how the current technology landscape changed following the publication of the ITC white paper and the progress we can expect to see in clinically relevant drug transporters.

This interview was created as a part of the pre-conference research for the 3rd Annual Clinically Relevant Drug Transporters, taking place from the 22nd- 24th  October, 2012 in London.

The interview helped to shape the summit agenda which features among others - Eva Gil Berglund, PhD, Medical Products Agency, Sweden and Keith Hoffmaster, Senior Investigator from Novartis (ITC member) who provide an insight into new developments in the FDA / EMA transporter interaction Draft Guidance Papers.

Other important topics which will be discussed at the event include:

  • Model-based Prediction of Transporter-mediated Disposition and DDIs (Manthena Varma, Principle Scientist, Pfizer)
  • Drug Targeting: how can we use Uptake Transporters to achieve CNS or Tumour Penetration  (Maarten Huisman, Janssen Pharmaceutical Companies)
  • De-risking conjugated metabolites for causing transporter DDI with toxicological implications (Timothy Shultz - Utermoehl, Shire Pharmaceuticals)
  • Impact of "transporter-metabolism" and "transporter-transporter" interplay in Raloxifene Disposition (Jae Chang, Research Scientist, Genentech)

Press are invited to attend this important industry forum. If you would like to a complimentary press pass please email Joanna Checinska (joanna.checinska@iqpc.co.uk)

To access Dr. James Clarke's full interview or find out more about the Clinically Relevant Drug Transporters Summit please visit http://www.drugrtransporters/news, email enquire@iqpc.co.uk or call +44(0)207-930-1300.

Media contact: Joanna Checinska, +44(0)20-7368-9807, joanna.checinska@iqpc.co.uk  - Please contact for more information or images.


'/>"/>
SOURCE Pharma IQ
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. GlaxoSmithKline Employees Embark on Long-Term Volunteer Assignments throughout the World
2. Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash
3. ResearchMoz: Telemedicine Monitoring Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018 - Market Research Report
4. Telemedicine Monitoring: Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018
5. Heska Announces Quarterly Dividend of $0.10 Per Share
6. I.V. Clinical Integration Helps Deliver Safety, Efficiency And Financial Benefits; Hospira Shares Snapshot Of Results, Process
7. OncoSec Medical Issues Letter to Shareholders
8. Cook Medical, Zimmer, Pro-Dex & J&J to Share Innovative Social Media Approaches to Marketing Device Products in Minneapolis
9. Lilly Declares Third-Quarter 2012 Dividend, Resumes Share Repurchase Program
10. Omnyx Share Their Insight on Agile Software Development for Medical Devices
11. Faruqi & Faruqi, LLP is Investigating Pain Therapeutics Inc. on Behalf of its Shareholders (PTIE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Stock-Callers.com today presents the following Generic ... CPRX ), Sophiris Bio Inc. (NASDAQ: SPHS ), ... Therapeutics Inc. (NASDAQ: AGRX ). These companies are ... late trade on Friday, January 20 th , 2017, with ... of health care companies in the S&P 500 also were ...
(Date:1/23/2017)... , January 23, 2017 The global  anxiety disorders and ... by 2025. The rising incidence of depression worldwide is anticipated to drive the ... resulted in the declining demand for antidepressants in the recent years. ... ... Grand View Research Logo ...
(Date:1/23/2017)... DIEGO and PALMA, Spain ... Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company ... that the first patient has been enrolled in ... lead candidate, SNF472, for the treatment of cardiovascular ... (HD). Most ESRD patients, in the ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 23, 2017 , ... The January 2017 issue of the ... study on how outdoor behavioral healthcare (OBH) – also known as wilderness therapy – ... while experiencing an increased sense of purpose both during and after treatment. , ...
(Date:1/24/2017)... ... January 23, 2017 , ... ... a new plugin that allows sleep centers to automatically connect and initialize all ... a thin client browser plugin is quickly installed on first use and then ...
(Date:1/23/2017)... Alto, CA (PRWEB) , ... ... ... a provider of translation and localization services for life science companies, has ... and inspection organization, TÜV SÜD America. ISO 17100 is the globally recognized ...
(Date:1/23/2017)... ... 23, 2017 , ... Wooden and plastic balance boards have been around since at least the ... Board is the first and only balance board to use a patent-pending design featuring ... at the same time as well as skill-level adjustable for all ages and abilities. ...
(Date:1/23/2017)... Indiana (PRWEB) , ... January 23, 2017 , ... ... Center for Assisted Living (IHCA/INCAL), will serve as a healthcare industry expert at ... 23. The panel discussion, moderated by Inside Indiana Business host Gerry Dick, will ...
Breaking Medicine News(10 mins):